A case of male breast cancer in which oncotype DX was used to determine the therapeutic strategy

Abstract Male breast cancer is rare, and reportedly to accounts for less than 1% of all breast cancers. Postoperative therapy of male breast cancer is similar to that for female cancer. We experienced a male patient and used oncotype DX to determine the therapeutic strategy. A 60-year-old man was diagnosed with breast cancer Stage I. He underwent sentinel lymph node biopsy and mastectomy, but lymph node dissection was omitted. However, micro-metastases were found in the permanent specimen. Later, axillary node dissection was performed. The patient was finally diagnosed with Stage IIA (T1c, N1mi, M0) and luminal A type breast cancer. From using oncotype DX to determine the therapeutic strategy, the recurrence score was 8 and within the low recurrence score group. Currently, we are only administering endocrine therapy.